查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1771740

肝病药物市场规模、份额、趋势分析报告：产品、疾病、地区、细分市场预测，2025-2033

Liver Disease Therapeutics Market Size, Share & Trends Analysis Report By Product (Antiviral Drugs, Vaccines, Chemotherapy), By Disease (Hepatitis, Autoimmune Diseases), By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

肝病药物市场的成长与趋势

根据Grand View Research, Inc.的最新报告，预计到2033年，全球肝病药物市场规模将达到402.9亿美元，2025年至2033年的复合年增长率为7.9%。主要驱动因素包括肝细胞癌等肝病发生率的上升，以及此类疾病患者巨大的未开发需求。此外，全球老龄人口的成长预计将推动未来市场需求的成长。

生物技术和製药行业在研发上的巨额投入以及强大的产品线预计将成为未来一段时间推动肝病药物市场成长的关键因素。各国政府和各大公司推出的疫苗接种计划提高了人们对肝病及其预防的认识，从而促进了市场的成长。

市场根据产品和地区划分为两个部分。新产品的快速推出推动了市场的成长。市场成长的动力源自于主要企业之间的策略联盟和合资企业，以及新兴国家日益增强的医疗保健意识。

肝病药物市场报告重点

  • 由于全球慢性病毒性肝炎盛行率高、乙肝治疗时间长、C肝 DAA 价格昂贵，抗病毒药物将在 2024 年占据市场主导地位，收入份额最大，为 39.84%。
  • 肝炎领域占据市场主导地位，2024 年的收入份额最大，为 40.44%。由于慢性肝炎的普遍负担和抗病毒治疗的临床成功，肝炎领域继续成为主要的市场驱动力。
  • 北美占据肝病药物市场的最大份额，占2024年全球收益的39.87%，受到肝病盛行率上升、人口老化和创新治疗方法的推动。
  • 由于乙肝和丙肝盛行率高、非酒精性脂肪肝 (NAFLD) 患者数量增加以及医疗保健基础设施不断改善，预计亚太地区肝病药物市场增长最快，预测期内复合年增长率为 9.19%。

目录

第一章调查方法与范围

第二章执行摘要

第三章肝病药物市场变数、趋势与范围

  • 市场体系展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 商业环境分析
    • 产业分析—波特五力分析
    • PESTLE分析
    • 管道分析
    • 专利到期分析
    • 定价分析

第四章肝病药物市场：产品业务分析

  • 2025年及2033年的产品市场占有率
  • 产品细分仪表板
  • 2021-2033 年市场规模及预测、产品趋势分析
  • 抗病毒药物
  • 疫苗
  • 化疗
  • 标靶治疗
  • 免疫抑制剂
  • 免疫球蛋白
  • 皮质类固醇
  • 其他的

第五章肝病药物市场：疾病业务分析

  • 2025年及2033年疾病市场占有率
  • 疾病细分仪表板
  • 2021-2033 年市场规模与预测、特定疾病趋势分析
  • 肝炎
  • 自体免疫疾病
  • 非酒精性脂肪肝（NAFLD）
  • 癌症
  • 遗传性疾病
  • 其他的

第六章肝病药物市场：区域、估计与趋势分析

  • 2025年及2033年区域市场占有率分析
  • 区域市场仪表板
  • 2021-2033年市场规模与预测趋势分析
  • 北美洲
    • 按国家/地区，2021-2033 年
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第七章 竞争态势

  • 参与者概览
  • 企业市场分析
  • 公司分类
  • 战略地图
  • 公司简介/上市公司
    • Gilead Sciences, Inc.
    • AbbVie Inc.
    • Bristol-Myers Squibb Company
    • F. Hoffmann-La Roche Ltd
    • Takeda Pharmaceutical Company Limited
    • Johnson & Johnson Services, Inc.
    • Merck & Co., Inc.
    • Novartis AG
    • Pfizer Inc.
    • Sanofi
    • GSK plc
Product Code: 978-1-68038-540-3

Liver Disease Therapeutics Market Growth & Trends:

The global liver disease therapeutics market size is expected to be valued at USD 40.29 billion by 2033, registering a CAGR of 7.9% from 2025 to 2033, according to a new report by Grand View Research, Inc. The major driving factors are increasing numbers of liver diseases like hepatocellular carcinoma and vast unexploited need of patients with these types of diseases. In addition, increasing geriatric population globally is estimated to augment the market demand in the future period.

Huge expenditure by biotechnology and pharmaceutical industries on R&D and availability of sturdy pipeline are the major expected boosting factors for the growth of liver diseases therapeutics market in future period. Governments' and big companies' vaccination program are creating awareness about the illness and prevention is boosting the growth of the market.

The market is bifurcated into products and regions. New products are rapidly being launched boosting the market growth. The growth of the market is boosted by the strategic alliances, joint venture between the major players, and growing awareness of healthcare in the upcoming nations.

Liver Disease Therapeutics Market Report Highlights:

  • The antiviral drugs segment dominated the market with the largest revenue share of 39.84% in 2024 due to the high global prevalence of chronic viral hepatitis, long treatment durations for HBV, and premium pricing for HCV DAAs.
  • The hepatitis segment dominated the market with the largest revenue share of 40.44% in 2024, attributed to the widespread burden of chronic hepatitis and the clinical success of antiviral treatments, the hepatitis segment remains a major market driver.
  • North America held the largest share of the liver disease therapeutics market in 2024, accounting for 39.87% of global revenue, driven by the rising prevalence of liver disease, aging populations, and breakthrough therapies.
  • The liver disease therapeutics market in Asia Pacific is projected to grow at the fastest CAGR of 9.19% over the forecast period, fueled by the high prevalence of hepatitis B and C, rising NAFLD cases, and improving healthcare infrastructure.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Disease
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Liver Disease Therapeutics Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Patent Expiry Analysis
    • 3.3.5. Pricing Analysis

Chapter 4. Liver Disease Therapeutics Market: Product Business Analysis

  • 4.1. Product Market Share, 2025 & 2033
  • 4.2. Product Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Product, 2021 to 2033 (USD Million)
  • 4.4. Antiviral Drugs
    • 4.4.1. Antiviral Drugs Market, 2021 - 2033 (USD Million)
  • 4.5. Vaccines
    • 4.5.1. Vaccines Market, 2021 - 2033 (USD Million)
  • 4.6. Chemotherapy
    • 4.6.1. Chemotherapy Market, 2021 - 2033 (USD Million)
  • 4.7. Targeted Therapy
    • 4.7.1. Targeted Therapy Market, 2021 - 2033 (USD Million)
  • 4.8. Immunosuppressants
    • 4.8.1. Immunosuppressants Market, 2021 - 2033 (USD Million)
  • 4.9. Immunoglobulins
    • 4.9.1. Immunoglobulins Market, 2021 - 2033 (USD Million)
  • 4.10. Corticosteroids
    • 4.10.1. Corticosteroids Market, 2021 - 2033 (USD Million)
  • 4.11. Other Products
    • 4.11.1. Other Products Market, 2021 - 2033 (USD Million)

Chapter 5. Liver Disease Therapeutics Market: Disease Business Analysis

  • 5.1. Disease Market Share, 2025 & 2033
  • 5.2. Disease Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Disease, 2021 to 2033 (USD Million)
  • 5.4. Hepatitis
    • 5.4.1. Hepatitis Market, 2021 - 2033 (USD Million)
  • 5.5. Autoimmune Diseases
    • 5.5.1. Autoimmune Diseases Market, 2021 - 2033 (USD Million)
  • 5.6. Non-alcoholic Fatty Liver Disease (NAFLD)
    • 5.6.1. Non-alcoholic Fatty Liver Disease (NAFLD) Market, 2021 - 2033 (USD Million)
  • 5.7. Cancer
    • 5.7.1. Cancer Market, 2021 - 2033 (USD Million)
  • 5.8. Genetic Disorders
    • 5.8.1. Genetic Disorders Market, 2021 - 2033 (USD Million)
  • 5.9. Other Diseases
    • 5.9.1. Other Diseases Market, 2021 - 2033 (USD Million)

Chapter 6. Liver Disease Therapeutics Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2025 & 2033
  • 6.2. Regional Market Dashboard
  • 6.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
  • 6.4. North America
    • 6.4.1. North America Liver Disease Therapeutics Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
    • 6.4.2. U.S.
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Target Disease Prevalence
      • 6.4.2.3. Regulatory Framework
      • 6.4.2.4. Reimbursement Framework
      • 6.4.2.5. U.S. Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.3. Canada
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Target Disease Prevalence
      • 6.4.3.3. Regulatory Framework
      • 6.4.3.4. Reimbursement Framework
      • 6.4.3.5. Canada Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.4. Mexico
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Target Disease Prevalence
      • 6.4.4.3. Regulatory Framework
      • 6.4.4.4. Reimbursement Framework
      • 6.4.4.5. Mexico Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Europe
    • 6.5.1. Europe Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.2. UK
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Target Disease Prevalence
      • 6.5.2.3. Regulatory Framework
      • 6.5.2.4. Reimbursement Framework
      • 6.5.2.5. UK Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.3. Germany
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Target Disease Prevalence
      • 6.5.3.3. Regulatory Framework
      • 6.5.3.4. Reimbursement Framework
      • 6.5.3.5. Germany Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.4. France
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Target Disease Prevalence
      • 6.5.4.3. Regulatory Framework
      • 6.5.4.4. Reimbursement Framework
      • 6.5.4.5. France Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.5. Italy
      • 6.5.5.1. Key Country Dynamics
      • 6.5.5.2. Target Disease Prevalence
      • 6.5.5.3. Regulatory Framework
      • 6.5.5.4. Reimbursement Framework
      • 6.5.5.5. Italy Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.6. Spain
      • 6.5.6.1. Key Country Dynamics
      • 6.5.6.2. Target Disease Prevalence
      • 6.5.6.3. Regulatory Framework
      • 6.5.6.4. Reimbursement Framework
      • 6.5.6.5. Spain Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.7. Denmark
      • 6.5.7.1. Key Country Dynamics
      • 6.5.7.2. Target Disease Prevalence
      • 6.5.7.3. Regulatory Framework
      • 6.5.7.4. Reimbursement Framework
      • 6.5.7.5. Denmark Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.8. Sweden
      • 6.5.8.1. Key Country Dynamics
      • 6.5.8.2. Target Disease Prevalence
      • 6.5.8.3. Regulatory Framework
      • 6.5.8.4. Reimbursement Framework
      • 6.5.8.5. Sweden Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.9. Norway
      • 6.5.9.1. Key Country Dynamics
      • 6.5.9.2. Target Disease Prevalence
      • 6.5.9.3. Regulatory Framework
      • 6.5.9.4. Reimbursement Framework
      • 6.5.9.5. Norway Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6. Asia Pacific
    • 6.6.1. Asia Pacific Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.2. Japan
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Target Disease Prevalence
      • 6.6.2.3. Regulatory Framework
      • 6.6.2.4. Reimbursement Framework
      • 6.6.2.5. Japan Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.3. China
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Target Disease Prevalence
      • 6.6.3.3. Regulatory Framework
      • 6.6.3.4. Reimbursement Framework
      • 6.6.3.5. China Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.4. India
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Target Disease Prevalence
      • 6.6.4.3. Regulatory Framework
      • 6.6.4.4. Reimbursement Framework
      • 6.6.4.5. India Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.5. Australia
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Target Disease Prevalence
      • 6.6.5.3. Regulatory Framework
      • 6.6.5.4. Reimbursement Framework
      • 6.6.5.5. Australia Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.6. South Korea
      • 6.6.6.1. Key Country Dynamics
      • 6.6.6.2. Target Disease Prevalence
      • 6.6.6.3. Regulatory Framework
      • 6.6.6.4. Reimbursement Framework
      • 6.6.6.5. South Korea Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.7. Thailand
      • 6.6.7.1. Key Country Dynamics
      • 6.6.7.2. Target Disease Prevalence
      • 6.6.7.3. Regulatory Framework
      • 6.6.7.4. Reimbursement Framework
      • 6.6.7.5. Thailand Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7. Latin America
    • 6.7.1. Latin America Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.2. Brazil
      • 6.7.2.1. Key Country Dynamics
      • 6.7.2.2. Target Disease Prevalence
      • 6.7.2.3. Regulatory Framework
      • 6.7.2.4. Reimbursement Framework
      • 6.7.2.5. Brazil Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.3. Argentina
      • 6.7.3.1. Key Country Dynamics
      • 6.7.3.2. Target Disease Prevalence
      • 6.7.3.3. Regulatory Framework
      • 6.7.3.4. Reimbursement Framework
      • 6.7.3.5. Argentina Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8. Middle East and Africa
    • 6.8.1. Middle East and Africa Liver Disease Therapeutics Market Estimates and Forecasts, 2017 - 2033 (USD Million)
    • 6.8.2. South Africa
      • 6.8.2.1. Key Country Dynamics
      • 6.8.2.2. Target Disease Prevalence
      • 6.8.2.3. Regulatory Framework
      • 6.8.2.4. Reimbursement Framework
      • 6.8.2.5. South Africa Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.3. Saudi Arabia
      • 6.8.3.1. Key Country Dynamics
      • 6.8.3.2. Target Disease Prevalence
      • 6.8.3.3. Regulatory Framework
      • 6.8.3.4. Reimbursement Framework
      • 6.8.3.5. Saudi Arabia Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.4. UAE
      • 6.8.4.1. Key Country Dynamics
      • 6.8.4.2. Target Disease Prevalence
      • 6.8.4.3. Regulatory Framework
      • 6.8.4.4. Reimbursement Framework
      • 6.8.4.5. UAE Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.5. Kuwait
      • 6.8.5.1. Key Country Dynamics
      • 6.8.5.2. Target Disease Prevalence
      • 6.8.5.3. Regulatory Framework
      • 6.8.5.4. Reimbursement Framework
      • 6.8.5.5. Kuwait Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Participant Overview
  • 7.2. Company Market Position Analysis
  • 7.3. Company Categorization
  • 7.4. Strategy Mapping
  • 7.5. Company Profiles/Listing
    • 7.5.1. Gilead Sciences, Inc.
      • 7.5.1.1. Overview
      • 7.5.1.2. Financial Performance
      • 7.5.1.3. Product Benchmarking
      • 7.5.1.4. Strategic Initiatives
    • 7.5.2. AbbVie Inc.
      • 7.5.2.1. Overview
      • 7.5.2.2. Financial Performance
      • 7.5.2.3. Product Benchmarking
      • 7.5.2.4. Strategic Initiatives
    • 7.5.3. Bristol-Myers Squibb Company
      • 7.5.3.1. Overview
      • 7.5.3.2. Financial Performance
      • 7.5.3.3. Product Benchmarking
      • 7.5.3.4. Strategic Initiatives
    • 7.5.4. F. Hoffmann-La Roche Ltd
      • 7.5.4.1. Overview
      • 7.5.4.2. Financial Performance
      • 7.5.4.3. Product Benchmarking
      • 7.5.4.4. Strategic Initiatives
    • 7.5.5. Takeda Pharmaceutical Company Limited.
      • 7.5.5.1. Overview
      • 7.5.5.2. Financial Performance
      • 7.5.5.3. Product Benchmarking
      • 7.5.5.4. Strategic Initiatives
    • 7.5.6. Johnson & Johnson Services, Inc.
      • 7.5.6.1. Overview
      • 7.5.6.2. Financial Performance
      • 7.5.6.3. Product Benchmarking
      • 7.5.6.4. Strategic Initiatives
    • 7.5.7. Merck & Co., Inc.
      • 7.5.7.1. Overview
      • 7.5.7.2. Financial Performance
      • 7.5.7.3. Product Benchmarking
      • 7.5.7.4. Strategic Initiatives
    • 7.5.8. Novartis AG
      • 7.5.8.1. Overview
      • 7.5.8.2. Financial Performance
      • 7.5.8.3. Product Benchmarking
      • 7.5.8.4. Strategic Initiatives
    • 7.5.9. Pfizer Inc.
      • 7.5.9.1. Overview
      • 7.5.9.2. Financial Performance
      • 7.5.9.3. Product Benchmarking
      • 7.5.9.4. Strategic Initiatives
    • 7.5.10. Sanofi
      • 7.5.10.1. Overview
      • 7.5.10.2. Financial Performance
      • 7.5.10.3. Product Benchmarking
      • 7.5.10.4. Strategic Initiatives
    • 7.5.11. GSK plc
      • 7.5.11.1. Overview
      • 7.5.11.2. Financial Performance
      • 7.5.11.3. Product Benchmarking
      • 7.5.11.4. Strategic Initiatives

List of Tables

  • Table 1. List of secondary sources
  • Table 2. List of abbreviations
  • Table 3. Global liver disease therapeutics market, by region, 2021 - 2033 (USD Million)
  • Table 4. Global liver disease therapeutics market, by product, 2021 - 2033 (USD Million)
  • Table 5. Global liver disease therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 6. North America liver disease therapeutics market, by country, 2021 - 2033 (USD Million)
  • Table 7. North America liver disease therapeutics market, by product, 2021 - 2033 (USD Million)
  • Table 8. North America liver disease therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 9. U.S. liver disease therapeutics market, by product, 2021 - 2033 (USD Million)
  • Table 10. U.S. liver disease therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 11. Canada liver disease therapeutics market, by product, 2021 - 2033 (USD Million)
  • Table 12. Canada liver disease therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 13. Mexico liver disease therapeutics market, by product, 2021 - 2033 (USD Million)
  • Table 14. Mexico liver disease therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 15. Europe liver disease therapeutics market, by country, 2021 - 2033 (USD Million)
  • Table 16. Europe liver disease therapeutics market, by product, 2021 - 2033 (USD Million)
  • Table 17. Europe liver disease therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 18. UK liver disease therapeutics market, by product, 2021 - 2033 (USD Million)
  • Table 19. UK liver disease therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 20. Germany liver disease therapeutics market, by product, 2021 - 2033 (USD Million)
  • Table 21. Germany liver disease therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 22. France liver disease therapeutics market, by product, 2021 - 2033 (USD Million)
  • Table 23. France liver disease therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 24. Italy liver disease therapeutics market, by product, 2021 - 2033 (USD Million)
  • Table 25. Italy liver disease therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 26. Spain liver disease therapeutics market, by product, 2021 - 2033 (USD Million)
  • Table 27. Spain liver disease therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 28. Norway liver disease therapeutics market, by product, 2021 - 2033 (USD Million)
  • Table 29. Norway liver disease therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 30. Denmark liver disease therapeutics market, by product, 2021 - 2033 (USD Million)
  • Table 31. Denmark liver disease therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 32. Sweden liver disease therapeutics market, by product, 2021 - 2033 (USD Million)
  • Table 33. Sweden liver disease therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 34. Asia Pacific liver disease therapeutics market, by country, 2021 - 2033 (USD Million)
  • Table 35. Asia Pacific liver disease therapeutics market, by product, 2021 - 2033 (USD Million)
  • Table 36. Asia Pacific liver disease therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 37. Japan liver disease therapeutics market, by product, 2021 - 2033 (USD Million)
  • Table 38. Japan liver disease therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 39. China liver disease therapeutics market, by product, 2021 - 2033 (USD Million)
  • Table 40. China liver disease therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 41. India liver disease therapeutics market, by product, 2021 - 2033 (USD Million)
  • Table 42. India liver disease therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 43. Australia liver disease therapeutics market, by product, 2021 - 2033 (USD Million)
  • Table 44. Australia liver disease therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 45. South Korea liver disease therapeutics market, by product, 2021 - 2033 (USD Million)
  • Table 46. South Korea liver disease therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 47. Thailand liver disease therapeutics market, by product, 2021 - 2033 (USD Million)
  • Table 48. Thailand liver disease therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 49. Latin America liver disease therapeutics market, by country, 2021 - 2033 (USD Million)
  • Table 50. Latin America liver disease therapeutics market, by product, 2021 - 2033 (USD Million)
  • Table 51. Latin America liver disease therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 52. Brazil liver disease therapeutics market, by product, 2021 - 2033 (USD Million)
  • Table 53. Brazil liver disease therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 54. Argentina liver disease therapeutics market, by product, 2021 - 2033 (USD Million)
  • Table 55. Argentina liver disease therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 56. Middle East & Africa Liver disease therapeutics market, by country, 2021 - 2033 (USD Million)
  • Table 57. Middle East & Africa liver disease therapeutics market, by product, 2021 - 2033 (USD Million)
  • Table 58. Middle East & Africa liver disease therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 59. South Africa liver disease therapeutics market, by product, 2021 - 2033 (USD Million)
  • Table 60. South Africa liver disease therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 61. Saudi Arabia liver disease therapeutics market, by product, 2021 - 2033 (USD Million)
  • Table 62. Saudi Arabia liver disease therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 63. UAE liver disease therapeutics market, by product, 2021 - 2033 (USD Million)
  • Table 64. UAE liver disease therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 65. Kuwait liver disease therapeutics market, by product, 2021 - 2033 (USD Million)
  • Table 66. Kuwait liver disease therapeutics market, by disease, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Liver disease therapeutics market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Therapeutic approach and application outlook (USD Million)
  • Fig. 10 Competitive landscape
  • Fig. 11 Liver disease therapeutics market dynamics
  • Fig. 12 Liver disease therapeutics market: Porter's five forces analysis
  • Fig. 13 Liver disease therapeutics market: PESTLE analysis
  • Fig. 14 Product market, 2021 - 2033 (USD Million)
  • Fig. 15 Antiviral drugs market, 2021 - 2033 (USD Million)
  • Fig. 16 Vaccines market, 2021 - 2033 (USD Million)
  • Fig. 17 Chemotherapy market, 2021 - 2033 (USD Million)
  • Fig. 18 Targeted therapy market, 2021 - 2033 (USD Million)
  • Fig. 19 Immunosuppressants market, 2021 - 2033 (USD Million)
  • Fig. 20 Immunoglobulins market, 2021 - 2033 (USD Million)
  • Fig. 21 Corticosteroids market, 2021 - 2033 (USD Million)
  • Fig. 22 Other products market, 2021 - 2033 (USD Million)
  • Fig. 23 Disease market, 2021 - 2033 (USD Million)
  • Fig. 24 Hepatitis market, 2021 - 2033 (USD Million)
  • Fig. 25 Autoimmune diseases market, 2021 - 2033 (USD Million)
  • Fig. 26 Non-alcoholic Fatty Liver Disease (NAFLD) market, 2021 - 2033 (USD Million)
  • Fig. 27 Cancer market, 2021 - 2033 (USD Million)
  • Fig. 28 Genetic disorders market, 2021 - 2033 (USD Million)
  • Fig. 29 Other diseases market, 2021 - 2033 (USD Million)
  • Fig. 30 Liver disease therapeutics market revenue, by region
  • Fig. 31 Regional marketplace: Key takeaways
  • Fig. 32 North America liver disease therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 33 U.S. country dynamics
  • Fig. 34 U.S. liver disease therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 35 Canada country dynamics
  • Fig. 36 Canada liver disease therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 37 Mexico country dynamics
  • Fig. 38 Mexico liver disease therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 39 Europe liver disease therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 40 UK country dynamics
  • Fig. 41 UK liver disease therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 42 Germany country dynamics
  • Fig. 43 Germany liver disease therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 44 France country dynamics
  • Fig. 45 France liver disease therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 46 Italy country dynamics
  • Fig. 47 Italy liver disease therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 48 Spain country dynamics
  • Fig. 49 Spain liver disease therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 50 Norway country dynamics
  • Fig. 51 Norway liver disease therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 52 Sweden country dynamics
  • Fig. 53 Sweden liver disease therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 54 Denmark country dynamics
  • Fig. 55 Denmark liver disease therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 56 Asia Pacific liver disease therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 57 Japan country dynamics
  • Fig. 58 Japan liver disease therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 59 China country dynamics
  • Fig. 60 China liver disease therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 61 India country dynamics
  • Fig. 62 India liver disease therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 63 Australia country dynamics
  • Fig. 64 Australia liver disease therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 65 South Korea country dynamics
  • Fig. 66 South Korea liver disease therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 67 Thailand country dynamics
  • Fig. 68 Thailand liver disease therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 69 Latin America liver disease therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 70 Brazil country dynamics
  • Fig. 71 Brazil liver disease therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 72 Argentina country dynamics
  • Fig. 73 Argentina liver disease therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 74 MEA liver disease therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 75 South Africa country dynamics
  • Fig. 76 South Africa liver disease therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 77 Saudi Arabia country dynamics
  • Fig. 78 Saudi Arabia liver disease therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 79 UAE country dynamics
  • Fig. 80 UAE liver disease therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 81 Kuwait country dynamics
  • Fig. 82 Kuwait liver disease therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 83 Company categorization
  • Fig. 84 Company market position analysis
  • Fig. 85 Strategic framework